Medical information notice: This article is for informational reference only. It does not constitute diagnosis, treatment, medication, or advice on seeking medical care in Japan, and it cannot replace in-person consultation with a physician. For matters involving medicines, examinations, clinical trials, or regenerative-medicine indications, please rely on the latest public information from medical institutions and competent authorities, and seek assessment by a qualified physician.
Information status: July 7, 2026. This article is compiled from public materials of Japan’s jRCT, the National Cancer Center Hospital, Sumitomo Heavy Industries, and others. BNCT treatment of thoracic tumors still falls within the scope of clinical research; this article does not constitute medical advice or a guarantee of trial enrollment.
In the past, the situation in which Chinese patients most often heard about BNCT was recurrent head and neck cancer. But Japan is now advancing it toward the harder-to-manage thoracic solid tumors. Japan’s clinical research registry, jRCT, shows that a Phase I/II basket trial numbered jRCT2031240246 is evaluating CICS-1 and SPM-011 for recurrent thoracic solid malignant tumors that are difficult to treat with standard therapy and are unresectable.
1. Why thoracic tumors are especially difficult
Around thoracic tumors there are critical organs such as the lungs, heart, esophagus, and spinal cord. Many patients with recurrence have already undergone surgery, radiotherapy, or systemic treatment, so when local treatment is attempted again, physicians must very carefully balance controlling the tumor against protecting normal tissue.
Re-irradiation with conventional radiotherapy may be limited by the prior dose. Surgery may be infeasible because of the location of the recurrence, adhesions, overall physical condition, or the risk of metastasis. It is precisely for this reason that new radiation-therapy approaches able to concentrate the dose more precisely continue to be explored.
2. The basic logic of BNCT
The core of BNCT is not simply “irradiation,” but a combination of a drug and a neutron beam. The patient first receives a boron-containing drug; ideally, tumor cells take up more boron than normal cells. Neutron irradiation then triggers a nuclear reaction, producing particles with a very short range and strong destructive power, thereby destroying, at the cellular scale, the tumor cells that contain more boron.
This principle sounds ideal, but the actual treatment effect depends on the uptake of the boron drug in the tumor, the depth of the tumor, the irradiation plan, the tolerable dose of normal organs, and the patient’s overall condition. BNCT is therefore not a universal solution suitable for all cancers.
3. What the jRCT2031240246 trial is studying
The T5267 page made public by Japan’s National Cancer Center Hospital shows that the trial targets patients with thoracic solid cancers, including directions such as esophageal cancer, non-small cell lung cancer, breast cancer, malignant soft-tissue sarcoma, malignant pleural mesothelioma, and malignant peripheral nerve sheath tumor. Core conditions include: aged 18 to 85; a pathological diagnosis of a thoracic solid malignant tumor; recurrence with standard radiotherapy or drug treatment being difficult; a lesion located below the thyroid and above the diaphragm; and a treatment plan judged able to achieve sufficient neutron irradiation.
Public materials show that this is a Phase I/II, open-label, single-arm basket trial, aimed at evaluating safety and efficacy, and at exploring the value of FBPA-PET in judging suitability for BNCT.
4. What a “basket trial” means
A basket trial does not study only one cancer, but places several cancer types that share a common treatment logic or common at-risk organs within the same research framework. Although thoracic tumors are different cancer types, in a BNCT treatment plan they all involve common at-risk organs such as the lungs, heart, esophagus, and spinal cord, so dose and safety can be evaluated with similar logic.
5. Why this trial is worth watching
- It advances BNCT further, from head and neck cancer toward thoracic solid tumors.
- It focuses on the patient population with recurrence, unresectable disease, and difficulty with standard treatment.
- Through examinations such as FBPA-PET, it attempts to screen in advance for patients more likely to be suitable for BNCT.
- It may provide new research evidence for scenarios such as thoracic recurrence of lung, esophageal, and breast cancer.
6. Limitations patients should know before consulting
First, a clinical trial is not routine treatment; enrollment criteria are strict, and meeting some conditions does not mean one can definitely be enrolled. Second, BNCT has requirements regarding lesion depth and boron-drug uptake; lesions that are deeper or too extensive are not necessarily suitable. Third, even after entering the trial, one needs to understand the potential adverse reactions and the uncertainty of efficacy.
Therefore, the truly meaningful first step is to prepare complete materials for an initial screening: pathology reports, DICOM imaging, prior radiotherapy doses, treatment history, current overall condition, and medication information.
Conclusion
The thoracic-tumor BNCT basket trial represents an important exploration by Japan in novel radiation therapy. It brings a new research direction for patients with recurrent thoracic tumors that are difficult to treat with standard therapy, but key questions such as safety, efficacy, and patient-selection criteria still need to be answered through clinical trials.